◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Direxion Daily S&P Biotech Bear 3X Shares (LABD) ETF Overview

Name: Direxion Daily S&P Biotech Bear 3X Shares (LABD) price history and fund statistics
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Price history, fund statistics and profile — an exchange-traded fund.

Exchange-Traded Funds · Trading--Inverse Equity · DATA UPDATED 2026-08-31

Direxion Daily S&P Biotech Bear 3X Shares (LABD) is an exchange-traded fund managed by Direxion Funds in the "Trading--Inverse Equity" category. It manages roughly $66 million in assets.

The fund, under normal circumstances, invests at least 80% of the fund’s net assets in financial instruments, including swap agreements, futures contracts, or short positions, that, in combination, provide 3X daily inverse (opposite) or short exposure to the index or to ETFs that track the index, consistent with the fund’s investment objective.

Interactive chart & fund stats →

LABD Fund Statistics

Expense ratio	1.07%
Trailing yield	6.96%
Assets under management	$66 million
Fund category	Trading--Inverse Equity
Fund family	Direxion Funds
Inception	2015-05-28

The live price chart, fund profile and news are in the interactive LABD viewer.

Other Companies in Trading--Inverse Equity

TSLS · Direxion Daily TSLA Bear 1X Shares — $81 million
SRTY · ProShares UltraPro Short Russell2000 — $80 million
DUST · Direxion Daily Gold Miners Index Bear 2X Shares — $71 million
TECS · Direxion Daily Technology Bear 3X Shares — $70 million
MUD · Direxion Daily MU Bear 1X Shares — $60 million
SNK · GraniteShares 2x Short SpaceX Daily ETF — $60 million
SKHU · Proshares Ultra Sk Hynix — $59 million
HDGE · AdvisorShares Ranger Equity Bear ETF — $57 million

← LAB All “L” companies LABS →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.